U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
99264
Substance Class Protein
Created
by admin
on Mon Oct 21 19:44:35 UTC 2019
Edited
by admin
on Mon Oct 21 19:44:35 UTC 2019
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
L0423Z5LDW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2C8
Common Name English
HUMAN CYTOCHROME P450 2C8
Common Name English
CYTOCHROME P 450 2C8
Common Name English
CYP2C8
Common Name English
CYP-2C8
Common Name English
CYP2C8 (HUMAN)
Common Name English
Code System Code Type Description
UNIPROT
P10632
Created by admin on Mon Oct 21 19:44:35 UTC 2019 , Edited by admin on Mon Oct 21 19:44:35 UTC 2019
PRIMARY
PUBCHEM
121225712
Created by admin on Mon Oct 21 19:44:35 UTC 2019 , Edited by admin on Mon Oct 21 19:44:35 UTC 2019
PRIMARY
CAS
330207-13-1
Created by admin on Mon Oct 21 19:44:35 UTC 2019 , Edited by admin on Mon Oct 21 19:44:35 UTC 2019
PRIMARY
Related Record Type Details
Structure of GRAZOPREVIR ANHYDROUS
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of VOXILAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of DASABUVIR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of SELEXIPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULPHOXIDE
INHIBITOR -> METABOLIC ENZYME
Structure of ROSIGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
Structure of TECOVIRIMAT
INHIBITOR -> METABOLIC ENZYME
MINOR
Structure of DRONEDARONE
INHIBITOR -> METABOLIC ENZYME
LOW
Ki
Structure of DUVELISIB
INHIBITOR -> METABOLIC ENZYME
Structure of OLACAFTOR
INHIBITOR -> METABOLIC ENZYME
Structure of VELPATASVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of OXYMETAZOLINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of CERLAPIRDINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of CARBAMAZEPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of GLECAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of REPAGLINIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of CLOPIDOGREL ACYL-.BETA.-D-GLUCURONIDE
INHIBITOR -> METABOLIC ENZYME
Structure of VECABRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of JD-5037
INHIBITOR -> METABOLIC ENZYME
Structure of PHENOBARBITAL
INDUCER -> METABOLIC ENZYME
Structure of AZD-1656
SUBSTRATE -> METABOLIC ENZYME
Structure of ISAVUCONAZOLE
INDUCER -> METABOLIC ENZYME
Structure of LURASIDONE
INHIBITOR -> METABOLIC ENZYME
MODERATE
Structure of SELEXIPAG
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TERIFLUNOMIDE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of AMIODARONE
SUBSTRATE -> METABOLIC ENZYME
Structure of COBICISTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of SIMEPREVIR
INHIBITOR -> METABOLIC ENZYME
CYP2C8
IC50
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of ELISMETREP
INHIBITOR -> METABOLIC ENZYME
Structure of TRIMETHOPRIM
INHIBITOR -> METABOLIC ENZYME
MAJOR
Ki
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of ISAVUCONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of ACT-333679
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of GLASDEGIB
SUBSTRATE -> METABOLIC ENZYME
Glasdegib is metabolized primarily by the CYP3A4 pathway, with minor contributions by CYP2C8 and UGT1A9
MINOR
Structure of CERIVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of BREXPIPRAZOLE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of CABAZITAXEL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of RIOCIGUAT
SUBSTRATE -> METABOLIC ENZYME
Structure of IMATINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of GEMFIBROZIL
INHIBITOR -> METABOLIC ENZYME
MAJOR
IC50
Structure of FLIBANSERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
MINOR
Structure of DEFERASIROX
INHIBITOR -> METABOLIC ENZYME
WEAK
IC50
Structure of LOMITAPIDE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ELAGOLIX
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of AMODIAQUINE
SUBSTRATE -> METABOLIC ENZYME
Structure of LORLATINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PACLITAXEL
SUBSTRATE -> METABOLIC ENZYME
Structure of ELTROMBOPAG
SUBSTRATE -> METABOLIC ENZYME
HM-43239
INHIBITOR -> METABOLIC ENZYME
Structure of SIMEPREVIR
SUBSTRATE -> METABOLIC ENZYME
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of RETAPAMULIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Structure of TAFENOQUINE
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of MONTELUKAST
SUBSTRATE -> METABOLIC ENZYME
Structure of DABRAFENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of BRIGATINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ALECTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORAMPHENICOL
NON-INHIBITOR -> METABOLIC ENZYME
Structure of RIFAMYCIN
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of OLODATEROL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ENZALUTAMIDE
SUBSTRATE -> METABOLIC ENZYME
In vivo, the sum of enzalutamide and M2 exposure was increased by 2.2-fold and 1.3-fold when it was co-administered with gemfibrozil (strong CYP2C8 inhibitor) or itraconazole (strong CYP3A4 inhibitor), respectively. If the co-administration of enzalutamide with a strong CYP2C8 inhibitor cannot be avoided, the daily enzalutamide dose should be reduced to 80 mg.
Structure of TRICLABENDAZOLE SULPHONE
INHIBITOR -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of AVATROMBOPAG
INDUCER -> METABOLIC ENZYME
In vitro data suggests that avatrombopag weakly induces CYP2C8 and CYP2C9
WEAK
Structure of LENVATINIB
METABOLIC ENZYME -> INHIBITOR
Structure of R-406
INDUCER -> METABOLIC ENZYME
Structure of APALUTAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of AZILSARTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of ELAGOLIX
INDUCER -> TARGET
Structure of PEXIDARTINIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of VERINURAD
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-06650833
NON-INHIBITOR -> METABOLIC ENZYME
Structure of ELAGOLIX
INHIBITOR -> TARGET
Ki
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966